Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Gain Therapeutics (GANX) Stock Price & Analysis
165 Followers
GANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.02 - $5.33
Previous Close$1.05
Volume231.88K
Average Volume (3M)286.77K
Market Cap
$18.95M
Enterprise Value$7.18M
Total Cash (Recent Filing)$12.66M
Total Debt (Recent Filing)$889.62K
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 07, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding18,051,979
10 Day Avg. Volume684,688
30 Day Avg. Volume286,770
Standard Deviation0.16
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit130.19
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$8.00Price Target Upside661.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Gain Therapeutics News
PremiumCompany Announcements
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
PremiumCompany Announcements
Gain Therapeutics Leadership Changes and Executive Compensation
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressGain Therapeutics announced the completion of dosing in the MAD portion of its Phase 1 study with no discontinuation or serious adverse events.
Preclinical DataRecent data demonstrated GT-02287 leads to improvements in cognitive performance in a mouse model of GBA1 Parkinson's disease.
Safety ProfileGT-02287 has shown a favorable safety and tolerability profile, with 90% of adverse events being mild and no Grade 3 or higher events reported.
Bears Say
Dilution RiskThe dilution from this most recent offering leads to a lowered 12-month price target from $9 to $8.
Price TargetFactoring-in dilution from the financing and a slightly higher discount rate, the price target is lowered to $5, from $10.
RisksRisks include, but are not limited to: delays in advancing preclinical candidates into clinical studies; unexpected safety issues; negative trial results; inability to advance into pivotal trials in a timely manner; failure to obtain regulatory approvals; slower than expected market uptake; partnership risks; and possible near to medium-term dilution risk.
---
Ownership Overview
1.97% Insiders
1.84% Mutual Funds
4.97% Other Institutional Investors
91.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $1.02 and its highest was $5.33 in the past 12 months.
What is Gain Therapeutics’s market cap?
Currently, no data Available
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 9 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on May 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.311 by $0.091.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -$0.22.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 18,051,980 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.311. Following the earnings report the stock price went down -3.306%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Among the largest hedge funds holding Gain Therapeutics’s share is Greenlight Capital Inc. It holds Gain Therapeutics’s shares valued at 2M.
---
Gain Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (661.90% Upside)
$8.00 (661.90% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $20.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.65%
12-Months-Change
Fundamentals
Return on Equity
-177.83%
Trailing 12-Months
Asset Growth
-31.63%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
---
GANX Stock 12 Month Forecast
Average Price Target
$8.00
▲(661.90% Upside)
Technical Analysis
Best Analysts Covering GANX
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-49.53%
reiterated a buy rating 6 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -49.53% per trade.
---